Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

A2250

Supelco

Warfarin

analytical standard

Sinonimo/i:

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumafene

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C19H16O4
Numero CAS:
Peso molecolare:
308.33
Beilstein:
8868198
Numero CE:
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24

Grado

analytical standard

Livello qualitativo

agenzia

EPA 1694

tecniche

HPLC: suitable
gas chromatography (GC): suitable

Punto di fusione

162-164 °C (lit.)

applicazioni

clinical testing

Formato

neat

Stringa SMILE

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
PJVWKTKQMONHTI-UHFFFAOYSA-N

Informazioni sul gene

human ... VKORC1(79001)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

Organi bersaglio

Blood

Codice della classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation.
Jeffrey I Weitz et al.
Circulation, 129(16), 1688-1694 (2014-04-23)
Daisuke Yoshioka et al.
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 17(4), 308-314 (2014-07-23)
The aim of this study was to evaluate our clinical experience with the Jarvik 2000 axial flow pump (Jarvik Heart, Inc, New York, NY, USA), a miniature axial flow left ventricular assist device (LVAD). The clinical results of eight patients
Ye Wang et al.
Cardiovascular drugs and therapy, 28(6), 575-585 (2014-10-17)
This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore. A Markov model was constructed to compare the lifetime costs, quality-adjusted life-years (QALYs)
Matthew W Sherwood et al.
Circulation, 129(18), 1850-1859 (2014-02-21)
During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, and
Shinji Kamisuki et al.
Journal of medicinal chemistry, 54(13), 4923-4927 (2011-05-13)
Fatostatin, a recently discovered small molecule that inhibits activation of sterol regulatory element-binding protein (SREBP), blocks biosynthesis and accumulation of fat in obese mice. We synthesized and evaluated a series of fatostatin derivatives. Our structure-activity relationships led to the identification

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.